BEAM insider sale: 25,000 shares via option exercise on 10/02/2025
Rhea-AI Filing Summary
An insider filing under Rule 144 discloses the proposed sale of 25,000 common shares of Beam Therapeutics (BEAM). The shares were acquired via a stock option exercise and paid in cash on 10/02/2025. The sale is to be executed through Morgan Stanley Smith Barney LLC with an indicated aggregate market value of $615,667.50 and the issuer's shares outstanding listed as 100,557,094. The filing also reports a prior sale of 25,000 shares on 10/01/2025 that generated $612,655.00 in gross proceeds. The filer certifies they are not aware of undisclosed material adverse information about the issuer.
Positive
- Transaction disclosed publicly under Rule 144 with broker identified
- Securities acquired via stock option exercise and paid in cash on the same date
Negative
- Insider sale of 25,000 shares on 10/02/2025 (aggregate value $615,667.50) which may increase share supply
- Prior sale of 25,000 shares on 10/01/2025 with $612,655.00 gross proceeds
Insights
Insider sold 25,000 shares following an option exercise on 10/02/2025.
The filing shows the shares were acquired by stock option exercise and paid in cash the same day, indicating the sale results from option liquidity rather than an open-market purchase. The transaction is routed through Morgan Stanley Smith Barney LLC with an aggregate market value of $615,667.50.
The filing also lists a separate sale of 25,000 shares on 10/01/2025 with $612,655.00 gross proceeds, showing consecutive insider dispositions. The filer affirms no undisclosed material adverse information.